RecruitingEarly Phase 1NCT07261306

Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Sponsor

Lahore General Hospital

Enrollment

75 participants

Start Date

Aug 29, 2025

Study Type

INTERVENTIONAL

Conditions

Psoriasis

Summary

Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Methotrexate and a drug called Tofacitinib for people with psoriasis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethotrexate

Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment

DRUGTofacitinib

Tofacitinib is janus kinase inhibitor and have role in psoriasis

Locations(1)

Lahore general hospital

Lahore, Punjab Province, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07261306

Related Trials

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT0748988520 locations

A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

NCT0758278319 locations